Liu Rong, Zhao Guo-Dong, Tang Wen-Bo, Zhang Ke-di, Zhao Zhi-Ming, Gao Yuan-Xing, Hu Ming-Gen, Li Cheng-Gang, Tan Xiang-Long, Zhang Xuan
Second Department of Hepatobiliary Surgery, General Hospital of PLA, Beijing 100853, China. E-mail:
Nan Fang Yi Ke Da Xue Xue Bao. 2018 Feb 20;38(2):130-134. doi: 10.3969/j.issn.1673-4254.2018.02.02.
To assess the safety and advantages of robotic pancreatic surgery (RPS) based on the single-team experience with 1010 cases.
The clinical data of 1010 cases of RPS performed by a single team from November, 2011 to September, 2017 in our hospital were collected prospectively and analyzed. In most of cases the surgeries were performed using the third-generation da Vinci robotic surgical system.
The 1010 cases receiving RPS included 417 cases of robotic pancreatoduodenectomy (RPD), 428 cases of robotic distal pancreatectomy, 60 cases of robotic central pancreatectomy, 53 cases of robotic pancreatic tumor enucleation, 3 cases of Appleby procedure, and 49 cases of other operations (including 4 cases of innovative robotic retroperitoneal laparoscopic surgery, 4 cases of robotic pancreatic tumor enucleation combined with main pancreatic duct bridging repair, 1 case of single incision robotic pancreatic tumor enucleation, and 2 cases of robotic central pancreatectomy combined with end-to-end anastomosis reconstruction). The median operative time was 210 min (30-720 min) with a median intraoperative blood loss of 80 mL (10-2000 mL), a conversion rate of 4.06% (41/1010), a blood transfusion rate of 6.7% (68/1010), a mean post-operative stay of 10.87∓6.70 days, a complication rate (beyond grade III according to Clavien-Dindo scoring system) of 8.0% (81/1010), and a pancreatic fistula rate (beyond) grade B of 9.21% (93/1010). The mortality rate of the patients was 0.69% (7/1010) in 30 days and 1.31% (12//934) in 90 days. The application of RPS in total pancreatectomy increased steadily from the rate of 10.44% in 2012 to 72.06% in 2017.
This represents to our knowledge the world largest series of robotic pancreatic resections. RPS is expected to gradually replace open procedure and laparoscopic procedure to become the primary choice of approach for pancreatectomy. After the learning curve, RPS procedure including distal pancreatectomy, robotic Appleby procedure and other operations can be safely performed, and the experiences from other centers can be beneficial to reduce severe complications in the early stage of learning.
基于单团队1010例的经验评估机器人胰腺手术(RPS)的安全性和优势。
前瞻性收集并分析2011年11月至2017年9月我院单团队实施的1010例RPS临床资料。多数手术使用第三代达芬奇机器人手术系统。
1010例接受RPS的患者中,包括417例机器人胰十二指肠切除术(RPD)、428例机器人远端胰腺切除术、60例机器人中央胰腺切除术、53例机器人胰腺肿瘤摘除术、3例Appleby手术以及49例其他手术(包括4例创新型机器人腹膜后腹腔镜手术、4例机器人胰腺肿瘤摘除术联合主胰管搭桥修复、1例单切口机器人胰腺肿瘤摘除术以及2例机器人中央胰腺切除术联合端端吻合重建)。中位手术时间为210分钟(30 - 720分钟),中位术中出血量为80毫升(10 - 2000毫升),中转率为4.06%(41/1010),输血率为6.7%(68/1010),平均术后住院时间为10.87±6.70天,并发症发生率(根据Clavien - Dindo评分系统超过Ⅲ级)为8.0%(81/1010),B级以上胰瘘发生率为9.21%(93/1010)。患者30天死亡率为0.69%(7/1010),90天死亡率为1.31%(12/934)。RPS在全胰切除术中的应用率从2012年的10.44%稳步上升至2017年的72.06%。
据我们所知,这是世界上最大规模的机器人胰腺切除术系列研究。RPS有望逐渐取代开放手术和腹腔镜手术,成为胰腺切除术的主要手术方式选择。经过学习曲线后,包括远端胰腺切除术、机器人Appleby手术及其他手术在内的RPS手术能够安全实施,其他中心的经验有助于在学习早期减少严重并发症的发生。